HealthQuad's first close of ₹550 Cr for Fund III targets AI healthcare and digital therapeutics. The fund's focus on India and Southeast Asia comes as healthtech funding dropped 40% YoY.
Alpha Score of 64 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
HealthQuad has closed the first tranche of its ₹1,700 Cr Fund III with ₹550 Cr in commitments, the firm said. New institutional and family office limited partners joined existing LPs in backing the vehicle.
The fund targets 13-15 healthtech startups across AI-driven healthcare, digital therapeutics, ambulatory care, enterprise SaaS, and point-of-care devices. Most of the capital will go to India, with a discretionary portion for Southeast Asia. HealthQuad has already made its first investment, an undisclosed sum in AI-driven patient monitoring platform LifeSigns, and is pursuing other proprietary deals.
HealthQuad Fund III is managed by HealthQuad Advisors, a vehicle fully owned by Quadria Group through Amit Varma, Abrar Mir and Thakur. The fund was originally launched in July last year with a target corpus of $300 Mn, after Quadria split from Belgium-based impact investor KIOS. Quadria took full control of HealthQuad ahead of Fund III. Operational leadership of HealthQuad simultaneously launched a separate firm called HealthKios, with its own maiden fund targeting $300 Mn plus a $100 Mn greenshoe.
HealthQuad's earlier two funds backed 18 healthtech startups including GoApptiv, Qure.ai, Redcliffe Labs, Cureskin, Strand Life Sciences, Medikabazaar, THB, Wysa, and Ekincare. Its second fund closed at $162 Mn.
The first close comes at a time when Indian healthtech funding has slowed. Twenty-five startups raised $181 Mn in Q1 2026, down 40% from $301 Mn in the same quarter last year, according to industry data. HealthQuad's ability to draw capital from both new and returning LPs suggests institutional appetite remains for early-growth healthcare plays, even as the broader funding environment tightens.
The fund's focus on AI-driven diagnostics, digital therapeutics, and point-of-care devices mirrors global trends where investors are betting on technology that reduces hospital dependency and improves access in underpenetrated markets. India's healthtech segment has produced strong innovations but historically lacked deep institutional backing. HealthQuad's third fund, at nearly three times the size of its second, indicates that gap may be narrowing for select managers.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.